Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Pediatrics. 2010 Sep 13;126(4):e796–e806. doi: 10.1542/peds.2010-0086

TABLE 5.

Adverse Effect Rates

Adverse Effect Baseline
Stimulant Monotherapy End Point
Aggression Responder Group
Aggression Refractory Group
χ2 (P) Aggression Responder Group
Aggression Refractory Group
χ2 (P)
n % n % n % n %
Abdominal pain 1 1 3 9 0 0 1 3
Anxiety or nervousness 4 15 7 22 4 13 8 26
Enuresis 2 6 1 3 1 3 1 3
Bite fingernails 4 15 8 25 4 13 5 16
Bruises easily 1 3 1 3 1 3 0 0
Crying 3 11 8 25 3 10 5 16
Insomnia, initial 6 22 15 47 3.88 (.05) 6 20 11 38
Decrease appetite 6 22 5 16 3 20 10 32
Diarrhea 1 3 0 0 1 3 1 3
Insomnia, middle 2 7 2 9 1 3 3 9
Dizzy 1 3 2 6 0 0 1 3
Dry mouth 1 4 3 10 1 3 1 3
Headache 5 19 1 3 3.80 (.05) 1 3 0 0
Increase appetite 2 7 4 13 0 0 1 3
Irritability 10 37 16 50 4 13 12 39 5.07 (.03)
Low energy 3 11 2 7 1 3 1 3
Nightmares 1 2 6 0 0 2 6
Rash 1 3 0 0 0 0 1 3
Restlessness 0 0 0 0 0 0 3 9 3.05 (.09)
Sadness 3 11 7 22 3 10 6 19
Shaking 1 3 0 0 1 3 1 3
Stares into space 2 7 3 9 1 3 2 6
Stomachache 2 7 2 7 2 7 3 10
Heart races 1 3 1 3 1 3 1 3
Less talkative 3 11 2 6 2 6 2 6
Overly talkative 10 37 8 25 3 10 5 16
Tics 2 6 2 6 2 7 1 3
Tired 1 3 1 3 1 3 1 3
Trouble waking 1 3 0 0 1 3 0 0
Tremors 1 3 0 0 0 0 2 6
Lack of interest 2 6 2 6 1 3 5 16 2.81 (.10)
Unusually happy 3 9 3 9 6 7 6 6
Early waking 3 11 7 22 3 10 3 9